ABL Bio Inc., a South Korean biotechnology firm, has signed a $2.6 billion licensing and joint analysis settlement with Eli Lilly and Co. for its proprietary blood–mind barrier shuttle platform often known as Grabody-B, marking one of many nation’s largest expertise switch offers this 12 months.
